Garset-Zamani, Martin, Hvilsom, Gitte Bjørn, Kjærgaard, Thomas, Plaschke, Christina Caroline, Hahn, Christoffer Holst, Kaltoft, Mikkel, O’Leary, Padraig, Frid, Natalie Lassen, Norling, Rikke, Dejanovic, Danijela, Hall, Johanna Maria, Agander, Tina Klitmøller, Nielsen, Signe Bergliot, Ersbøll, Annette Kjær, Wessel, Irene, Buchwald, Christian von, Todsen, Tobias, Garset-Zamani, Martin, Hvilsom, Gitte Bjørn, Kjærgaard, Thomas, Plaschke, Christina Caroline, Hahn, Christoffer Holst, Kaltoft, Mikkel, O’Leary, Padraig, Frid, Natalie Lassen, Norling, Rikke, Dejanovic, Danijela, Hall, Johanna Maria, Agander, Tina Klitmøller, Nielsen, Signe Bergliot, Ersbøll, Annette Kjær, Wessel, Irene, Buchwald, Christian von, and Todsen, Tobias
This study protocol for a prospective, multicenter, diagnostic, clinical trial describes the integration of transoral and transcervical ultrasonography (US) in the initial clinical work-up of patients referred to tertiary head and neck cancer centers with suspected oropharyngeal cancer. The study evaluates the blinded detection rate of oropharyngeal tumors and their US-estimated size and T-stage before histopathology and cross-sectional imaging are available. Magnetic resonance imaging (MRI) scans will be prospectively rated while blinded to T-site histopathology and US. The primary outcome measures of diagnostic accuracy, including sensitivity, specificity, positive and negative predictive values, and overall accuracy, will be reported for both US and MRI. A sub-analysis of prospectively rated 18F-Fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) scans in patients with clinically suspected unknown primary tumors will also be compared to US and MRI. Secondary outcome measures, including a comparison of tumor size estimation between US, MRI, and CT, will also be reported. This prospective multicenter study will provide clinically impactful information regarding the use of transoral and transcervical US for the diagnostic work-up of oropharyngeal cancer., This study protocol for a prospective, multicenter, diagnostic, clinical trial describes the integration of transoral and transcervical ultrasonography (US) in the initial clinical work-up of patients referred to tertiary head and neck cancer centers with suspected oropharyngeal cancer. The study evaluates the blinded detection rate of oropharyngeal tumors and their US-estimated size and T-stage before histopathology and cross-sectional imaging are available. Magnetic resonance imaging (MRI) scans will be prospectively rated while blinded to T-site histopathology and US. The primary outcome measures of diagnostic accuracy, including sensitivity, specificity, positive and negative predictive values, and overall accuracy, will be reported for both US and MRI. A sub-analysis of prospectively rated 18F-Fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) scans in patients with clinically suspected unknown primary tumors will also be compared to US and MRI. Secondary outcome measures, including a comparison of tumor size estimation between US, MRI, and CT, will also be reported. This prospective multicenter study will provide clinically impactful information regarding the use of transoral and transcervical US for the diagnostic work-up of oropharyngeal cancer.